药物缓释微球TACE对比传统碘油TACE治疗不可切除肝癌：倾向性评分匹配

目的比较药物缓释微球TACE（DEB-TACE）与传统碘油TACE（c-TACE）治疗不可切除肝癌的临床疗效。 方法回顾性分析2015年9与至2020年7月我院治疗120例原发性肝癌的临床资料，其中DEB-TACE组30例、c-TACE组90例。按1∶1进行配对后分析两种治疗方式的临床效果。首要观察指标为患者的肿瘤无进展生存期，次要观察指标是1、3、6、12个月疾病控制、客观缓解率和术后并发症。 结果实际完成配对患者23对，配对后两组间基线特征具有可比性，结果示DEB-TACE相比c-TACE治疗原发性肝癌的中位无疾病进展期分别为3、10个月（P = 0.002）。DEB-TACE组1、3、6、12个月的客观缓解率（69%、78%、60%、52%）明显高于c-TACE组客观缓解率（39%、39%、26%、8%） （P < 0.05）。DEB-TACE组术后3个月的疾病控制率95%明显高于c-TACE组73%（P < 0.05）。术后肝脓肿患者1例（DEB-TACE组1例），引流后患者恢复良好，余均无严重并发症发生。 结论DEB-TACE治疗不可切除性肝癌在肿瘤控制方面优于c-TACE，具有更好的临床获益。

Drug-eluting bead TACE versus conventional iodide TACE in the treatment of unresectable liver cancer: propensity score matching analysis

ObjectiveTo compare the clinical efficacy of drug-eluting bead TACE (DEB-TACE) and conventional iodide TACE (c-TACE) in the treatment of unresectable liver cancer. MethodsThe clinical data of 120 cases of primary liver cancer treated in our hospital from September 2015 to July 2020 were retrospectively analyzed, including 30 cases in DEB-TACE group and 90 cases in c-TACE group. The clinical effects of the two treatments were analyzed after 1∶1 matching. Primary outcome measures were tumor time to progression and secondary outcome measures were disease control, objective response rate and postoperative complications at 1, 3, 6 and 12 months. ResultsTwenty-three pairs of patients were actually matched, and the baseline characteristics of the two groups were comparable. The median time to tumor progression period of DEB-TACE compared with c-TACE for primary liver cancer was 3 months and 10 months (P = 0.002). The Objective Remission Rate of DEB-TACE group were significantly higher than those of c-TACE group at 1, 3, 6 and 12 months (69%, 78%, 60% and 52% vs 39%, 39%, 26% and 8%, P < 0.05). The Disease Control Rate at 3 months after operation in DEB-TACE group was significantly higher than that in c-TACE group (95% vs 73%, P < 0.05). There was 1 case of postoperative liver abscess (1 case in DEB-TACE group). The patients recovered well after drainage, and there were no serious complications. ConclusionsDEB-TACE is superior to c-TACE in tumor control in patients with unresectable liver cancer and has better clinical benefits.